Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Breast Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 45 articles: HTML format Text format

Single Articles

January 2012
1. MIEOG JS , Morden JP, Bliss JM, Coombes RC, et al
   Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
   Lancet Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. MASUDA N , Sagara Y, Kinoshita T, Iwata H, et al
   Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
   Lancet Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. KELLY CM , Buzdar AU
   Aromatase inhibitors in premenopausal breast cancer.
   Lancet Oncol. 2012.
   PubMed     Text format     Related articles   
   
   
   
   
4. BADVE S , Nakshatri H
   Breast-cancer stem cells-beyond semantics.
   Lancet Oncol. 2012;13:e43-8.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
5. GIANNI L , Pienkowski T, Im YH, Roman L, et al
   Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
   Lancet Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. GALGUT C
   Psychological effect of breast cancer.
   Lancet Oncol. 2011;12:1187.
   PubMed     Text format     Related articles   
   
   
   
   November 2011
7. ZAHL PH , Gotzsche PC, Maehlen J
   Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study.
   Lancet Oncol. 2011;12:1118-24.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. BONNEFOI HR
   Anthracyclines, HER2, and TOP2A: the verdict.
   Lancet Oncol. 2011;12:1084-5.
   PubMed     Text format     Related articles   
   
   
   
   October 2011
9. REGAN MM , Neven P, Giobbie-Hurder A, Goldhirsch A, et al
   Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up.
   Lancet Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. KALAGER M
    Regression of screening-detected breast cancer.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
11. NORMANNO N , De Luca A, Gallo M, Lamura L, et al
    Zoledronic acid in early-stage breast cancer.
    Lancet Oncol. 2011;12:991.
    PubMed     Text format     Related articles   
    
    
    
    
12. KUNZMANN V , Wilhelm M
    Adjuvant zoledronic acid for breast cancer: mechanism of action?
    Lancet Oncol. 2011;12:991-2.
    PubMed     Text format     Related articles   
    
    
    
    September 2011
13. LEO AD , Desmedt C, Bartlett JM, Piette F, et al
    HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. MOELANS CB , Reis-Filho JS, van Diest PJ
    Implications of rarity of chromosome 17 polysomy in breast cancer.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
15. BROWER V
    US court reverses gene patent ruling for BRCA1 and BRCA2.
    Lancet Oncol. 2011;12:835.
    PubMed     Text format     Related articles   
    
    
    
    
16. TELLI ML
    PARP inhibitors in cancer: moving beyond BRCA.
    Lancet Oncol. 2011;12:827-8.
    PubMed     Text format     Related articles   
    
    
    
    August 2011
17. GELMON KA , Tischkowitz M, Mackay H, Swenerton K, et al
    Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. WEIDHAAS J , Slack F, Miller N, Harris L, et al
    Association between KRAS rs61764370 and triple-negative breast cancer-a false positive? - Authors' reply.
    Lancet Oncol. 2011;12:724.
    PubMed     Text format     Related articles   
    
    
    
    
19. PHAROAH P , Antoniou A, Berchuck A, Chenevix-Trench G, et al
    Association between KRAS rs61764370 and triple-negative breast cancer-a false positive?
    Lancet Oncol. 2011;12:723-4.
    PubMed     Text format     Related articles   
    
    
    
    
20. CARLSON RH
    Bevacizumab: public opinion might trump science.
    Lancet Oncol. 2011;12:730.
    PubMed     Text format     Related articles   
    
    
    
    July 2011
21. BRUFSKY A
    Adjuvant bisphosphonates for early-stage breast cancer.
    Lancet Oncol. 2011;12:610-1.
    PubMed     Text format     Related articles   
    
    
    
    June 2011
22. LOI S , Symmans WF, Bartlett JM, Fumagalli D, et al
    Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. GNANT M , Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, et al
    Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. DE LAURENTIIS M
    Optimum chemotherapy regimen for early breast cancer.
    Lancet Oncol. 2011;12:514-5.
    PubMed     Text format     Related articles   
    
    
    
    May 2011
25. OOSTENDORP LJ , Stalmeier PF, Donders AR, van der Graaf WT, et al
    Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. BONNEFOI H , Piccart M, Bogaerts J, Mauriac L, et al
    TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. BURKI T
    Cancer mortality in Northern Ireland.
    Lancet Oncol. 2011;12:428.
    PubMed     Text format     Related articles   
    
    
    
    April 2011
28. NAROD SA
    Genetic variants associated with breast-cancer risk.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
29. ZHANG B , Beeghly-Fadiel A, Long J, Zheng W, et al
    Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
30. ANDERSON BO , Cazap E, El Saghir NS, Yip CH, et al
    Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010.
    Lancet Oncol. 2011;12:387-98.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
31. CUZICK J , Decensi A, Arun B, Brown PH, et al
    Preventive therapy for breast cancer: a consensus statement.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. KUMAR MS , Swanton C
    KRAS 3'-UTR variants and stratification of breast-cancer risk.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
33. PARANJAPE T , Heneghan H, Lindner R, Keane FK, et al
    A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. MARTIN M , Roche H, Pinter T, Crown J, et al
    Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. BUZDAR AU
    Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
36. HARFORD JB
    Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all.
    Lancet Oncol. 2011;12:306-12.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. LEYLAND-JONES B , Smith BR
    Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
    Lancet Oncol. 2011;12:286-95.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
38. BOZOVIC-SPASOJEVIC I , Azim HA Jr, Paesmans M, Suter T, et al
    Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
39. GIANNI L , Dafni U, Gelber RD, Azambuja E, et al
    Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. BONNEFOI H , Potti A, Delorenzi M, Mauriac L, et al
    Retraction-validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
    Lancet Oncol. 2011;12:116.
    PubMed     Text format     Related articles   
    
    
    
    January 2011
41. KUERER HM
    Rational individualised selection of adjuvant therapy for ductal carcinoma in situ.
    Lancet Oncol. 2011;12:2-3.
    PubMed     Text format     Related articles   
    
    
    
    
42. CUZICK J , Sestak I, Pinder SE, Ellis IO, et al
    Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
    Lancet Oncol. 2011;12:21-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
43. BANERJEE S , Smith IE
    Management of small HER2-positive breast cancers.
    Lancet Oncol. 2010;11:1193-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. GNANT M
    10 years of ATAC: one question answered, many others unresolved.
    Lancet Oncol. 2010;11:1109-10.
    PubMed     Text format     Related articles   
    
    
    
    October 2010
45. MCCUAIG JM , Greenwood C, Shuman C, Chitayat D, et al
    Breast and ovarian cancer: Y do we forget about dad?
    Lancet Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: